Prestige Consumer Healthcare Inc
Prestige Consumer Healthcare Inc/ US74112D1019 /
PBH
2024-04-26 9:59:42 PM
|
Chg.
+0.47
|
Volume |
Bid- |
Ask- |
Market Capitalization |
Dividend Y. |
P/E Ratio |
70.53USD
|
+0.66%
|
7,267 Turnover: 509,793.16 |
-Bid Size: - |
-Ask Size: - |
3.5 bill.USD |
- |
- |
Business description
Prestige Consumer Healthcare, Inc. markets and distributes brand name over-the-counter healthcare products throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s brands include Monistat® and Summer’s Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® eye care products, DenTek® and The Doctor's® oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® sore throat treatments, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Efferdent® denture care products, Luden's® throat drops, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia.
Management board & Supervisory board
CEO |
Ron Lombardi |
Management board |
Christine Sacco, Adel Mekhail, Jeff Thompson, Jeff Zerillo, Mary Beth Fritz, William P'Pool |
Supervisory board |
Ron Lombardi, Christopher J. Coughlin, Dawn M. Zier, Dr. Celeste A. Clark, Dr. Gary E. Costley, James M. Jenness, John E. Byom, Natale S. Ricciardi, Sheila A. Hopkins |
Company data
Name: |
Prestige Consumer Healthcare, Inc. |
Address: |
660 White Plains Road,Tarrytown, New York 10591, USA |
Phone: |
+1-914-524-6800 |
Fax: |
- |
E-mail: |
Irinquiries@prestigebrands.com
|
Internet: |
www.prestigebrandsinc.com/ |
Industry: |
Consumer Goods |
Sector: |
Cosmetics |
Sub sector: |
Cosmetics |
End of financial year: |
03-31 |
Free Float: |
69.88% |
IPO date: |
- |
Investor relations
Name: |
Phil Terpolilli |
IR phone: |
+1-914-524-6819 |
IR Fax: |
- |
IR e-mail: |
-
|
Main Shareholders
Freefloat |
|
69.88% |
BlackRock, Inc. |
|
12.50% |
The Vanguard Group |
|
10.72% |
Dimensional Fund Advisors LP |
|
6.90% |